Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. CANCER LICENSE AGREEMENTCancer License Agreement • June 3rd, 2016 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS CANCER LICENSE AGREEMENT (this “Agreement”) dated as of September 11, 2015 (the “Effective Date”) is entered into between TMRC Co., Ltd., a Japanese corporation having a place of business at 1-12-12, Kita Shinjuku, Shinjuku-ku, Tokyo 164-0074, Japan (“TMRC”) and Syros Pharmaceuticals, Inc., a Delaware corporation having a place of business at 620 Memorial Drive, Suite 300, Cambridge MA 02139 USA (“Syros”).
AMENDMENT NO. 1 TO AMENDED AND RESTATED CANCER LICENSE AGREEMENTCancer License Agreement • May 6th, 2021 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Amendment to Amended and Restated License Agreement (this “Amendment”) is made as of January 8, 2021 by and between Syros Pharmaceuticals, Inc., a Delaware corporation having a place of business at 35 CambridgePark Drive, 4th Floor, Cambridge, Massachusetts 02140 USA (“Syros”) TMRC Co., Ltd., a Japanese corporation having a place of business at 1-12-12, Kita Shinjuku, Shinjuku-ku, Tokyo 164-0074, Japan (“TMRC”).
AMENDED AND RESTATED CANCER LICENSE AGREEMENTCancer License Agreement • March 7th, 2019 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED CANCER LICENSE AGREEMENT (this “Agreement”) dated as of April 28, 2016 (the “Restatement Date”) is entered into between TMRC Co., Ltd., a Japanese corporation having a place of business at 1-12-12, Kita Shinjuku, Shinjuku-ku, Tokyo 164-0074, Japan (“TMRC”) and Syros Pharmaceuticals, Inc., a Delaware corporation having a place of business at 620 Memorial Drive, Suite 300, Cambridge MA 02139 USA (“Syros”).
